UPDATE 1-Regeneron to report $400 mln 4th quarter Eylea sales-CEO

Jan 14 (Reuters) - Regeneron Pharmaceuticals Inc will report about $400 million in U.S. sales of its high-profile eye drug Eylea for the fourth quarter of 2013, bringing the total for the year to about $1.4 billion with lots of room for future sales growth, the U.S. biotech company's chief executive said on Tuesday.

from Reuters: Company News http://feeds.reuters.com/~r/reuters/companyNews/~3/n2aOe8GS1mc/story01.htm

via IFTTT